Telix Pharmaceuticals' stock is under pressure, with shares sinking due to various factors, including regulatory scrutiny and financial pressures. The company's shares have fallen, with some reports citing a specific decline, although the extent of the decline is unclear. Some analysts see potential for the stock to rebound, with one broker predicting a significant upside.